Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pfizer
Pharma
Pfizer eyes earlier Talzenna use after ph. 3 prostate cancer win
If approved, Talzenna would be the first PARP inhibitor to enter the HRR-mutant metastatic hormone-sensitive prostate cancer setting.
Angus Liu
Mar 19, 2026 6:45am
The top 10 drugs losing US exclusivity in 2026
Mar 16, 2026 3:00am
Pfizer CEO Albert Bourla earns 2025 pay bump to $27.6M
Mar 13, 2026 11:26am
FDA signs off on GSK's Arexvy for at-risk adults ages 18-49
Mar 13, 2026 11:07am
Lilly, Pfizer-Sciwind, Astellas—Fierce Pharma Asia
Mar 13, 2026 8:05am
Lilly shines in Q4 as peers brace for 2026 slowdown
Mar 11, 2026 3:00pm
